Abstract | BACKGROUND: Exchange transfusion is a mainstay in the treatment of sickle cell anemia. Transfusion recipients with sickle cell disease (SCD) can be transfused over 10 units per therapy, an intervention that replaces circulating sickle red blood cells (RBCs) with donor RBCs. Storage of RBCs makes the intervention logistically feasible. The average storage duration for units transfused at the Duke University Medical Center is approximately 2 weeks, a time window that should anticipate the accumulation of irreversible storage lesion to the RBCs. However, no metabolomics study has been performed to date to investigate the impact of exchange transfusion on recipients' plasma and RBC phenotypes. STUDY DESIGN AND METHODS: Plasma and RBCs were collected from patients with sickle cell anemia before transfusion and within 5 hours after exchange transfusion with up to 11 units, prior to metabolomics analyses. RESULTS: CONCLUSION: Metabolic phenotypes confirm the benefits of the transfusion therapy in transfusion recipients with SCD and the reversibility of some of the metabolic storage lesion upon transfusion in vivo in 2-week-old RBCs. However, results also suggest that potentially harmful plasticizers are transfused.
|
Authors | Rachel Culp-Hill, Amudan J Srinivasan, Sarah Gehrke, Reed Kamyszek, Andrea Ansari, Nirmish Shah, Ian Welsby, Angelo D'Alessandro |
Journal | Transfusion
(Transfusion)
Vol. 58
Issue 12
Pg. 2797-2806
(12 2018)
ISSN: 1537-2995 [Electronic] United States |
PMID | 30265764
(Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2018 AABB. |
Topics |
- Adult
- Anemia, Sickle Cell
(blood, therapy)
- Blood Preservation
- Erythrocyte Transfusion
- Erythrocytes
(metabolism)
- Female
- Humans
- Male
- Metabolomics
- Plasma
(metabolism)
|